Phase I Studies of Peptide Vaccine Cocktails Derived from GPC3, WDRPUH and NEIL3 for Advanced Hepatocellular Carcinoma

References

• Singal AG , LamperticoP , NahonP. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J. Hepatol.72(2), 250–261 (2020).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD , JemalA. Cancer statistics, 2020. CA Cancer J. Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• Zhu RX , SetoWK , LaiCL , YuenMF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver.10(3), 332–339 (2016).
   PubMed Web of Science ®Google Scholar
• Tateishi R , UchinoK , FujiwaraNet al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J. Gastroenterol.54(4), 367–376 (2019).
   PubMed Web of Science ®Google Scholar
• Uchino K , TateishiR , ShiinaSet al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer117(19), 4475–4483 (2011).
   PubMed Web of Science ®Google Scholar
• Villanueva A . Hepatocellular carcinoma. N. Engl. J. Med.380, 1450–1462 (2019).
   PubMed Web of Science ®Google Scholar
• Longo V , GnoniA , CasadeiGardini Aet al. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget8(20), 33897–33910 (2017).
   PubMedGoogle Scholar
• Nakatsura T , YoshitakeY , SenjuSet al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun.306(1), 16–25 (2003).
   PubMed Web of Science ®Google Scholar
• Nishida T , KataokaH. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers (Basel)11(9), 1339 (2019).
   PubMed Web of Science ®Google Scholar
• Jing JS , YeW , JiangYKet al. The value of GPC3 and GP73 in clinical diagnosis of hepatocellular carcinoma. Clin. Lab.63(11), 1903–1909 (2017).
   PubMed Web of Science ®Google Scholar
• Silva FP , HamamotoR , NakamuraY , FurukawaY. WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation. Neoplasia7(4), 348–355 (2005).
   PubMed Web of Science ®Google Scholar
• Rolseth V , KrokeideSZ , KunkeDet al. Loss of Neil3, the major DNA glycosylase activity for removal of hydantoins in single stranded DNA, reduces cellular proliferation and sensitizes cells to genotoxic stress. Biochim. Biophys. Acta1833(5), 1157–1164 (2013).
   PubMed Web of Science ®Google Scholar
• Sejersted Y , HildrestrandGA , KunkeDet al. Endonuclease VIII-like 3 (Neil3) DNA glycosylase promotes neurogenesis induced by hypoxia-ischemia. Proc. Natl Acad. Sci. USA108(46), 18802–18807 (2011).
   PubMed Web of Science ®Google Scholar
• Shinmura K , KatoH , KawanishiYet al. Abnormal expressions of DNA glycosylase genes NEIL1, NEIL2, and NEIL3 are associated with somatic mutation loads in human cancer. Oxid. Med. Cell. Longev.2016, 1546392 (2016).
   PubMed Web of Science ®Google Scholar
• Liu M , DoubliéS , WallaceSS. Neil3, the final frontier for the DNA glycosylases that recognize oxidative damage. Mutat. Res.743–744, 4–11 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang H , MaH , WangQet al. Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol. Rep.23(2), 445–455 (2010).
   PubMed Web of Science ®Google Scholar
• HLA Laboratory . HLA affinity in Japanese population 2012. (2012). http://hla.or.jp/med/frequency_search/en/allele/
   Google Scholar
• Japan Clinical Oncology Group . National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 Japanese translation Japan Clinical Oncology Group (JCOG) version. www.jcog.jp/doctor/tool/ctcaev4.html
   Google Scholar
• Eisenhauer EA , TherasseP , BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y , YamaueH , OkusakaTet al. The Committee of Guidance for Peptide Vaccines for the Treatment of Cancer, The Japanese Society for Biological Therapy. Guidance for peptide vaccines for the treatment of cancer. Cancer Sci.105(7), 924–931 (2014).
   PubMed Web of Science ®Google Scholar
• U. S. Department of Health and Human Services,Food and Drug Administration, Center for Biologics Evaluation and Research . Guidance for industry clinical considerations for therapeutic cancer vaccines. (2011). www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-considerations-therapeutic-cancer-vaccines
   Google Scholar
• Sawada Y , YoshikawaT , NobuokaDet al. Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunological evidence and potential for improving overall survival. Clin. Cancer Res.18(13), 3686–3896 (2012).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr , YamshchikovG , NeeseP , GalavottiH , EasthamS , EngelhardVH. Phase I trial of a melanoma vaccine with gp100 (280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res.7(10), 3012–3024 (2001).
   PubMed Web of Science ®Google Scholar
• Lienard D , RimoldiD , MarchandMet al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun.4, 4 (2004).
   PubMedGoogle Scholar
• Odunsi K , QianF , MatsuzakiJ , Mhawech-FaucegliaP , AndrewsC , HoffmanEW. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA104(31), 12837–13842 (2007).
   PubMed Web of Science ®Google Scholar
• Oka Y , TsuboiA , TaguchiTet al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101(38), 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Kono K , IinumaH , AkutsuYet al. Multicenter, Phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J. Transl. Med.10, 141 (2012).
   PubMed Web of Science ®Google Scholar
• Yorita K , OhnoA , NishidaT , KondoK , OhtomoT , KataokaH. Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Res. Notes.12(1), 741 (2019).
   PubMed Web of Science ®Google Scholar
• Nowicki TS , Hu-LieskovanS , RibasA. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J.24(1), 47–53 (2018).
   PubMed Web of Science ®Google Scholar
• Togashi Y , ShitaraK , NishikawaH. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat. Rev. Clin. Oncol.16(6), 356–371 (2019).
   PubMed Web of Science ®Google Scholar
• Lindau D , GielenP , KroesenM , WesselingP , AdemaGJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology138(2), 105–115 (2013).
   PubMed Web of Science ®Google Scholar
• Chanmee T , OntongP , KonnoK , ItanoN. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel)6(3), 1670–1690 (2014).
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB , SangroB , YauTet al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase I/II dose escalation and expansion trial. Lancet389(10088), 2492–2502 (2017).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK , MeyerT , ChengALet al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med.379(1), 54–63 (2018).
   PubMed Web of Science ®Google Scholar
• Finn RS , QinS , IkedaMet al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med.382(20), 1894–1905 (2020).
   PubMed Web of Science ®Google Scholar
• Benson B , D’AngelicaMI , AbbottDEet al. NCCN guidelines (Hepatobiliary Cancers). www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
   Google Scholar
• Gnoni A , SantiniD , ScartozziMet al. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin. Ther. Targets 19(12), 1623–1635 (2015).
   PubMed Web of Science ®Google Scholar